ZA200805609B - Mesenchymal stem cells expressing TNF-α receptor - Google Patents

Mesenchymal stem cells expressing TNF-α receptor

Info

Publication number
ZA200805609B
ZA200805609B ZA200805609A ZA200805609A ZA200805609B ZA 200805609 B ZA200805609 B ZA 200805609B ZA 200805609 A ZA200805609 A ZA 200805609A ZA 200805609 A ZA200805609 A ZA 200805609A ZA 200805609 B ZA200805609 B ZA 200805609B
Authority
ZA
South Africa
Prior art keywords
receptor
stem cells
cells expressing
mesenchymal stem
expressing tnf
Prior art date
Application number
ZA200805609A
Other languages
English (en)
Inventor
Danilkovitch Alia
Carter Diane
Tyrell Alicia
Bubnic Simon
Marcelino Michelle
Monroy Rodney
Original Assignee
Osiris Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osiris Therapeutics Inc filed Critical Osiris Therapeutics Inc
Publication of ZA200805609B publication Critical patent/ZA200805609B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA200805609A 2006-01-13 2008-06-26 Mesenchymal stem cells expressing TNF-α receptor ZA200805609B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75915706P 2006-01-13 2006-01-13

Publications (1)

Publication Number Publication Date
ZA200805609B true ZA200805609B (en) 2009-04-29

Family

ID=38309740

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200805609A ZA200805609B (en) 2006-01-13 2008-06-26 Mesenchymal stem cells expressing TNF-α receptor

Country Status (11)

Country Link
US (9) US20090169522A1 (xx)
EP (3) EP1971679B1 (xx)
CN (1) CN101370930A (xx)
AU (1) AU2007208504B2 (xx)
BR (1) BRPI0706529A2 (xx)
CA (2) CA2893204C (xx)
ES (1) ES2415855T3 (xx)
HK (1) HK1151553A1 (xx)
MX (2) MX348735B (xx)
WO (1) WO2007087139A2 (xx)
ZA (1) ZA200805609B (xx)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298862B1 (en) 2004-03-22 2017-08-30 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
EP1976977B1 (en) 2005-12-29 2015-07-08 Anthrogenesis Corporation Placental stem cell populations
EP1971679B1 (en) * 2006-01-13 2013-04-10 Osiris Therapeutics, Inc. Mesenchymal stem cells expressing tnf- receptor
KR20200011604A (ko) 2008-08-20 2020-02-03 안트로제네시스 코포레이션 개선된 세포 조성물 및 그의 제조 방법
AU2009283161A1 (en) 2008-08-22 2010-02-25 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
US8367409B2 (en) 2008-11-19 2013-02-05 Anthrogenesis Corporation Amnion derived adherent cells
US9192695B2 (en) 2008-11-20 2015-11-24 Allosource Allografts combined with tissue derived stem cells for bone healing
AU2010325546B2 (en) * 2009-11-27 2014-10-16 Stempeutics Research Pvt. Ltd. Methods of preparing mesenchymal stem cells, compositions and kit thereof
WO2011127113A1 (en) 2010-04-08 2011-10-13 Anthrogenesis Corporation Treatment of sarcoidosis using placental stem cells
US9408873B2 (en) 2010-08-23 2016-08-09 Kang Stem Biotech Co., Ltd. Pharmaceutical composition comprising stem cells treated with NOD2 agonist or culture thereof for prevention and treatment of immune disorders and inflammatory diseases
US9677042B2 (en) 2010-10-08 2017-06-13 Terumo Bct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
US20120087933A1 (en) 2010-10-08 2012-04-12 Samson Tom Enhanced msc preparations
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
CN113559126A (zh) 2011-06-01 2021-10-29 人类起源公司 利用胎盘干细胞治疗疼痛
AU2012279995C1 (en) 2011-07-06 2019-10-24 Cell Therapy Limited Progenitor cells of mesodermal lineage
WO2014150784A1 (en) 2013-03-15 2014-09-25 Allosource Cell repopulated collagen matrix for soft tissue repair and regeneration
US9617506B2 (en) 2013-11-16 2017-04-11 Terumo Bct, Inc. Expanding cells in a bioreactor
EP3613841B1 (en) 2014-03-25 2022-04-20 Terumo BCT, Inc. Passive replacement of media
EP3198006B1 (en) 2014-09-26 2021-03-24 Terumo BCT, Inc. Scheduled feed
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
EP3656842A1 (en) 2017-03-31 2020-05-27 Terumo BCT, Inc. Cell expansion
AU2018262788A1 (en) 2017-05-04 2019-11-14 Mesoblast International Sàrl Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
CN111565731B (zh) 2017-10-24 2024-03-08 达莉亚·伊兰妮 治疗缺血性疾病的方法
CN110938668A (zh) * 2019-11-21 2020-03-31 北京贝来生物科技有限公司 一种间充质干细胞生物学效力的检测方法
AU2021323475A1 (en) * 2020-08-10 2023-04-13 Mesoblast International Sarl A composition comprising mesenchymal precursor or stem cells and their use
WO2024009226A1 (en) * 2022-07-05 2024-01-11 Mesoblast International Sarl Cryopreserved intermediate and potency assay for same

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6156304A (en) * 1990-12-20 2000-12-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education Gene transfer for studying and treating a connective tissue of a mammalian host
US6071889A (en) * 1991-07-08 2000-06-06 Neurospheres Holdings Ltd. In vivo genetic modification of growth factor-responsive neural precursor cells
AU2701895A (en) 1994-06-07 1996-01-05 Regents Of The University Of Minnesota Methods for inhibiting antigen specific t cell responses
US6974571B2 (en) 1995-03-28 2005-12-13 Thomas Jefferson University Isolated stromal cells and methods of using the same
US5955257A (en) * 1997-10-21 1999-09-21 Regents Of The University Of Minnesota Infusible grade short-term cell storage medium for mononuclear cells
US6251295B1 (en) 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
AU755888B2 (en) * 1998-03-18 2003-01-02 Mesoblast International Sarl Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US6368636B1 (en) 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
JP2002510655A (ja) 1998-04-03 2002-04-09 オシリス セラピューティクス，インコーポレイテッド 免疫抑制剤としての間葉幹細胞によるｔ細胞応答を阻害する方法とその利用
CA2328425A1 (en) 1998-05-22 1999-12-02 Osiris Therapeutics, Inc. Production of megakaryocytes by co-culturing human mesenchymal stem cells with cd34+ cells
US6007995A (en) * 1998-06-26 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of TNFR1 expression
AUPQ147799A0 (en) 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
US8147824B2 (en) * 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
EP1218489B1 (en) * 1999-09-24 2009-03-18 Cybios LLC Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
US6797514B2 (en) * 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7144729B2 (en) * 2000-09-01 2006-12-05 Dfb Pharmaceuticals, Inc. Methods and compositions for tissue regeneration
AU2002311777A1 (en) * 2001-04-17 2002-10-28 Genetix Pharmaceuticals, Inc. Method of treating arthritis using lentiviral vectors in gene therapy
US8404229B2 (en) 2001-12-07 2013-03-26 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to treat acute tubular necrosis
US8105580B2 (en) 2001-12-07 2012-01-31 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to promote wound healing
ITTO20020311A1 (it) 2002-04-10 2003-10-10 Medestea Int Spa Procedimento per la preparazione di cellule staminali da tessuto muscolare e tessuto adiposo umano e cellule staminali ottenibili mediante t
US20060134596A1 (en) * 2003-05-08 2006-06-22 Anita Sjogren Cryopreservation of human blastocyst-derived stem cells by use of a closed straw vitrification method
EP2298862B1 (en) * 2004-03-22 2017-08-30 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
US20080095749A1 (en) 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
US20060063141A1 (en) * 2004-09-17 2006-03-23 Mcgann Locksley E Method of cryopreserving cells
EP1795588A1 (en) * 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
US20070253931A1 (en) 2006-01-12 2007-11-01 Osiris Therapeutics, Inc. Use of mesenchymal stem cells for treating genetic diseases and disorders
EP1971679B1 (en) * 2006-01-13 2013-04-10 Osiris Therapeutics, Inc. Mesenchymal stem cells expressing tnf- receptor
KR100908481B1 (ko) 2006-04-24 2009-07-21 코아스템(주) 중간엽 줄기세포 배양 배지 및 이를 이용한 중간엽줄기세포의 배양 방법
WO2010019886A1 (en) 2008-08-14 2010-02-18 Osiris Therapeutics, Inc. Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions
US20120087933A1 (en) 2010-10-08 2012-04-12 Samson Tom Enhanced msc preparations
AU2015371011B2 (en) 2014-12-23 2021-07-15 Mesoblast International Sàrl Prevention of progressive heart failure
BR112020010079A2 (pt) 2017-11-22 2020-11-03 Mesoblast International Sàrl composições celulares e métodos de tratamento i
BR112021013158A2 (pt) 2019-01-02 2021-09-14 Mesoblast International Sàrl Método para tratar a dor lombar
BR112021012923A2 (pt) 2019-01-03 2021-09-14 Mesoblast International Sàrl Método para melhorar a acuidade visual
WO2020157660A1 (en) 2019-01-28 2020-08-06 Mesoblast International Sárl Method for treating or preventing gastrointestinal bleeding
US20220226386A1 (en) 2019-05-23 2022-07-21 Mesoblast International Sárl Functional recovery from cerebral infarction
CN114423860A (zh) 2019-08-05 2022-04-29 迈索布拉斯特国际有限公司 包含病毒载体的细胞组合物及治疗方法
CN115361960A (zh) 2020-02-19 2022-11-18 迈索布拉斯特国际有限公司 用于治疗慢性移植物抗宿主病的方法
KR20220152240A (ko) 2020-03-11 2022-11-15 메조블라스트 인터내셔널 에스에이알엘 염증성 장 질환 ii의 치료 방법

Also Published As

Publication number Publication date
EP1971679A2 (en) 2008-09-24
US20070258963A1 (en) 2007-11-08
CN101370930A (zh) 2009-02-18
CA2893204A1 (en) 2007-08-02
MX348735B (es) 2017-06-27
US8486695B2 (en) 2013-07-16
EP2465922B1 (en) 2018-08-01
BRPI0706529A2 (pt) 2011-03-29
WO2007087139A2 (en) 2007-08-02
EP3287520A1 (en) 2018-02-28
US20210171913A1 (en) 2021-06-10
EP1971679B1 (en) 2013-04-10
EP2465922A2 (en) 2012-06-20
US20090169522A1 (en) 2009-07-02
CA2893204C (en) 2016-11-29
MX2008008774A (es) 2008-09-26
AU2007208504A1 (en) 2007-08-02
US11821004B2 (en) 2023-11-21
US20110189768A1 (en) 2011-08-04
CA2635915C (en) 2015-09-08
US20140248244A1 (en) 2014-09-04
US20130259841A1 (en) 2013-10-03
EP2465922A3 (en) 2012-12-05
US20150004693A1 (en) 2015-01-01
US20180087032A1 (en) 2018-03-29
EP1971679A4 (en) 2009-12-09
WO2007087139A3 (en) 2007-10-11
HK1151553A1 (en) 2012-02-03
ES2415855T3 (es) 2013-07-29
AU2007208504B2 (en) 2011-04-21
US20120214178A1 (en) 2012-08-23
CA2635915A1 (en) 2007-08-02

Similar Documents

Publication Publication Date Title
ZA200805609B (en) Mesenchymal stem cells expressing TNF-α receptor
PL2254586T3 (pl) Cząstki mezenchymalnych komórek macierzystych
HK1155312A1 (en) Optimized serving dual cell change
PL2046946T3 (pl) Hodowla pluripotencjalnych komórek macierzystych
IL197444A0 (en) Cell culture improvements
GB0605450D0 (en) Cell co-culture
HK1129703A1 (en) Abcb5 positive mesenchymal stem cells as immunomodulators abcb5
EP2315829A4 (en) INDUCED PLURIPOTENT STEM CELLS
EP2184349A4 (en) ISOLATED CELL MASS
GB0907978D0 (en) Multipotent adult stem cell population
SG10201403202XA (en) Pre-natal mesenchymal stem cells
ZA201000715B (en) Single pluripotent stem cell culture
IL201102A0 (en) Fast serving cell change
PT2205721T (pt) Células tr1, células-tronco mesenquimais e usos das mesmas
EP2028264A4 (en) CELL INCUBATOR
GB2465732B (en) Methods and assays for screening stem cells
GB0606671D0 (en) Cell Culture
GB0604170D0 (en) T cell assays
GB0600960D0 (en) Whole cell biosensor
GB0602208D0 (en) Embryonic stem cells
GB0724994D0 (en) Mesenchymal stem cell markers
GB0619251D0 (en) T cell therapies
GB0818256D0 (en) stem cells
GB0602082D0 (en) Cells
PL380136A1 (pl) Ogniwo fotowoltaiczne